Comparison of 'sequential' versus 'standard' chemotherapy as re-induction treatment, with or without cyclosporine, in refractory/relapsed acute myeloid leukaemia (AML): Results of the UK Medical Research Council AML-R trial

British Journal of Haematology

Volumn 113, Issue 3, 2001, Pages 713-726

  Liu Yin, John A ^a   Wheatley, Keith ^b   Rees, John K H ^c   Burnett, Alan K ^d  

^a MANCHESTER ROYAL INFIRMARY   (United Kingdom)

^b UNIVERSITY OF BIRMINGHAM   (United Kingdom)

^c ADDENBROOKE S HOSPITAL   (United Kingdom)

^d CARDIFF UNIVERSITY   (United Kingdom)

Author keywords

Cyclosporine; Re induction chemotherapy; Refractory relapsed AML; Sequential

Indexed keywords

CYCLOSPORIN A; CYTARABINE; DAUNORUBICIN; ETOPOSIDE;

ACUTE MYELOBLASTIC LEUKEMIA; ADOLESCENT; ADULT; AGED; ALGORITHM; ARTICLE; BLOOD TOXICITY; CANCER CHEMOTHERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER RECURRENCE; CANCER REGRESSION; CANCER RESEARCH; CANCER SURVIVAL; CHILD; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; FEMALE; HUMAN; INFANT; MAJOR CLINICAL STUDY; MALE; MULTIDRUG RESISTANCE; PRESCHOOL CHILD; PRIORITY JOURNAL; PROGNOSIS; RANDOMIZED CONTROLLED TRIAL; SCHOOL CHILD; UNITED KINGDOM;

ACUTE DISEASE; ADOLESCENT; ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CHILD; CHILD, PRESCHOOL; CYCLOSPORINE; CYTARABINE; DAUNORUBICIN; DISEASE-FREE SURVIVAL; DRUG ADMINISTRATION SCHEDULE; ETOPOSIDE; FEMALE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; LEUKEMIA, MYELOID; MALE; MIDDLE AGED; REMISSION INDUCTION;

EID: 0034988112     PISSN: 00071048     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2141.2001.02785.x     Document Type: Article

References (45)

1. Treatment of refractory and relapsed acute myelogenous leukemia with combination chemotherapy plus the multidrug resistance modulator PSC833 (valspodar)
2. Intensive sequential chemotherapy with mitrozantrone and continuous infusion etoposide and cytarabine for previously treated acute myelogenous leukemia
3. Phase III study of PSC-833 modulation of multidrug resistance (MDR) in previously untreated acute myeloid leukaemia (AML) patients >60yrs (CALGB 9720)
4. Phase 1 trial of high dose tamoxifen as a modulator of drug resistance in combination with daunorubicin in patients with relapsed or refractory AML
5. A randomized study of high-dose cytarabine in induction acute myeloid leukaemia
6. A rationale sequential high-dose chemotherapy of leukaemia timed to coincide with induced tumour proliferation
7. Clinical significance of multidrug resistance P-glycoprotein on acute nonlymphocytic leukemia cells at diagnosis
8. Drug-resistance in multiple myeloma and non-Hodgkin's lymphoma: Detection of P-glycoprotein and potential circumvention by addition of verapamil to chemotherapy
9. A stratification system for evaluating therapies in patients with relapsed or primary myeloid leukemia
10. Intensive timed chemotherapy protocol for 37 resistant or relapsing acute myeloid leukemias
11. A two-step time sequential treatment for acute myeloid leukemia
12. Treatment of refractory/relapsed AML with PBC 833 plus mitoxantrone, etoposide, cytarabine (PSC-MEC) vs MEC: Randomized phase 111 trial (E 2995)
13. Randomized comparison of DAT versus ADE as induction chemotherapy in children and younger adults with acute myeloid leukemia. Results of the Medical Research Council's 10th AML Trial (MRC AML 10)
14. Expression of mdr1 and mdr3 multidrug resistance genes in human and chronic leukemias and association with stimulation of drug accumulation by cyclosporine
15. Treatment strategies in acute myeloid leukemia (AML) B. Second line treatment
16. Definition of refractoriness against conventional chemotherapy in acute myeloid leukemia: A proposal based on the results of re-treatment by thioguanine, cytosine, arabinoside and daunorubicin (TAD 9) in 150 patients with relapse after standardised first line therapy
17. Enhancement of drug cytotoxicity by recruitment of leukemic myeloblasts with humoral stimulation
18. Growth response of residual leukemia after initial drug therapy
19. Phase 1 study of mitoxantrone plus etoposide with multidrug blockade by SDZ PSC - 833 in relapsed or refractory AML
20. Acute myeloid leukemia in the elderly: Assessment of MDR-1 and cytogenetics distinguishes biologic subgroups with remarkably distant responses to standard chemotherapy. A SWOG Study
21. Multidrug resistance and its pharmacologic modulation in acute myeloid leukemia
22. Expression of the multidrug resistance gene product (P-glycoprotein) in myelodysplasia is associated with a stem cell phenotype
23. Phase I/II trial of cyclosporine as a chemotherapy resistance modifier in acute leukemia
24. Benefit of cyclosporine (CSA) modulation of anthracycline resistance in high-risk AML. A Southwest Oncology Group (SWOG) Study
25. Treatment of the elderly patient with acute myeloid leukaemia
26. Multidrug resistance (mdr 1) gene expression in adult acute leukemias: Correlations with treatment outcome and in vitro drug sensitivity
27. Effects of verapamil on the cellular accumulation of daunorubicin in blast cells and the chemosensitivity of leukaemic blast progenitors in acute myelogenous leukaemia
28. Intensive post-remission chemotherapy in adults with acute myeloid leukemia
29. Over expression of the mdr1 gene in blast cells from patients with acute myelocytic leukemia is associated with stimulation of drug accumulation that can be restored by cyclosporine A
30. Systemic toxic effects associated with high dose verapamil infusion and chemotherapy administration
31. MRD 1 gene expression and treatment outcome in acute myeloid leukemia
32. Principal results of the Medical Research Council's 8th acute myeloid leukaemia trial
33. MDR1 transcripts levels as an indication of resistant disease in acute myelogenous leukaemia
34. Cyclosporine A reverses vincristine and daunorubicin resistance in acute lymphatic leukemia in vitro
35. Combination of quinine as a potential reversing agent with mitozantrone and cytarabine for the treatment of acute leukemias. A randomized multicentre study
36. Reversal of drug-resistance by cyclosporine A in a patient with acute myelocytic leukaemia
37. Duration of second complete remission in patients with acute myeloid leukemia treated with chemotherapy: A retrospective single-centre study
38. Overcoming of vincristine resistance in P388 leukemia in vivo and in vitro through enhanced cytotoxicity of vincristine and vinblastine by verapamil
39. Long chemotherapy-free remission after single-cycle time sequential chemotherapy for acute myelocytic leukemia
40. Two-cycle timed-sequential chemotherapy for adult acute nonlymphocytic leukemia
41. A phase III trial of high-dose cytosine arabinoside with or without etoposide in relapsed and refractory acute myelogenous leukemia. A South-Eastern Cancer Study Group Trial
42. Outcome for children with relapsed acute myeloid leukemia following initial therapy in the Medical Research Council (MRC) AML 10 trial
43. Impact of re-induction regimens on the clinical course of adult acute nonlymphocytic leukemia
44. A simple, robust and highly predictive prognostic index for the determination of risk-directed therapy in acute myeloid leukaemia derived from the MRC AML 10 trial
45. P-glycoprotein expression on acute myeloid leukaemia blast cells at diagnosis predicts response to chemotherapy and survival